Welcome to our dedicated page for GSK plc SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc received approval in China for Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least one prior therapy.
The decision by China’s National Medical Products Administration followed priority review and Breakthrough Therapy Designation for the regimen. It is the only anti-BCMA option approved in second line and beyond multiple myeloma in China, and the only fully outpatient anti-BCMA therapy, allowing 30-minute infusions without hospitalisation.
The DREAMM-7 phase III trial showed the Blenrep combination nearly tripled median progression-free survival to 36.6 months versus 13.4 months for a daratumumab-based triplet, and reduced the risk of death by 42%. Three-year overall survival was 74% for the Blenrep regimen versus 60% for the comparator, with safety broadly consistent with known profiles and manageable eye-related side effects.
GSK plc reports that on 17 April 2026, it repurchased 330,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,115.00p to 2,137.00p per share, with a volume‑weighted average price of 2,126.15p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 19,856,521 ordinary shares. After this transaction, it holds 259,747,615 shares in treasury and has 4,056,451,419 shares in issue (excluding treasury shares), which is also the total number of voting rights. Treasury shares represent 6.40% of voting rights.
GSK plc reports that, acting through BNP Paribas, it purchased 330,000 ordinary shares of 31¼ pence each on 16 April 2026 as part of its existing share buyback programme. The shares were bought at prices between 2,116.00p and 2,136.00p, with a volume‑weighted average price of 2,125.06p, and will be held as Treasury shares.
GSK states that since 17 February 2026 it has purchased 19,526,521 ordinary shares under this programme. Following the latest transaction, it holds 259,417,615 ordinary shares in treasury and has 4,056,773,154 ordinary shares in issue excluding treasury shares, which is also the total number of voting rights in the company.
The company confirms that, in line with DTR 5.5.1R, the percentage of voting rights attributable to the ordinary shares held in treasury is 6.39%. Investors may use the updated total voting rights figure of 4,056,773,154 as the denominator when assessing whether disclosure thresholds under the Financial Conduct Authority’s rules are met.
GSK plc reports that multiple senior executives and non-executive directors increased their holdings in its equity through dividend reinvestment plans. On 9 April 2026, cash dividends were reinvested into Ordinary Shares and American Depositary Shares held in the Company’s Deferred Annual Bonus Plan, a pension plan, or directly.
On 14 April 2026, CEO Luke Miels received a notional increase of 1,178 Ordinary Shares at £21.6700, and CFO Julie Brown received 1,553 Ordinary Shares at £21.6700. Other executives, including the Chief People Officer, Chief Digital and Technology Officer, and President, Corporate Development, received smaller Ordinary Share or ADS allocations at similar prices.
Several independent non-executive directors, such as Charles Bancroft and Dr Hal Barron, acquired modest amounts of ADS (for example 313 ADS at $58.9307) via dividend reinvestment on the New York Stock Exchange. These are plan-based acquisitions rather than open-market trading decisions.
GSK plc reports that on 15 April 2026 it repurchased 325,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought at prices between 2,142.00p and 2,201.00p with a volume-weighted average price of 2,179.65p per share and will be held as Treasury shares.
The purchases were made under a non-discretionary agreement with the broker announced on 17 February 2026, since when GSK has repurchased 19,196,521 ordinary shares. After this transaction, GSK holds 259,087,615 shares in treasury and has 4,057,103,154 ordinary shares in issue, which is also the total number of voting rights.
GSK confirms that, in line with DTR 5.5.1R, the voting rights attributable to the ordinary shares held in treasury represent 6.39%. Detailed schedules list the quantities and prices executed across trading venues BATE, CHIX and XLON as part of the buyback activity.
GSK plc has completed its acquisition of 35Pharma Inc., a private, Canada-based clinical-stage biopharma company, for $950 million. The deal brings HS235, a potential best-in-class therapy targeting the activin receptor signalling pathway for pulmonary hypertension (PH), into GSK’s respiratory, immunology and inflammation pipeline.
HS235 is designed with enhanced selectivity intended to reduce bleeding and other adverse events seen with current pulmonary arterial hypertension treatments, and early studies have suggested possible metabolic benefits such as fat-selective weight loss and improved insulin sensitivity. GSK highlights that PH affects about 82 million people worldwide with limited treatment options and around 50% five-year survival, and plans to start proof-of-concept trials in pulmonary arterial hypertension and PH due to heart failure with preserved ejection fraction imminently.
GSK plc reports that, acting through BNP Paribas, it repurchased 325,000 ordinary shares on 14 April 2026 under its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,164.00p and 2,194.00p, with a volume‑weighted average price of 2,176.46p per share.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought back a total of 18,871,521 ordinary shares. After this transaction, the company holds 258,762,615 ordinary shares in treasury and has 4,057,428,154 ordinary shares in issue, which is also the total number of voting rights.
GSK notes that, in line with DTR 5.5.1R, 6.38% of its voting rights are now represented by ordinary shares held in treasury. The filing also provides detailed trade-by-trade disclosure across London Stock Exchange and CBOE Europe venues as part of the programme.
GSK plc reports that, acting through BNP Paribas, it repurchased 325,000 ordinary shares of 31¼ pence each on 13 April 2026 at prices between 2,154.00p and 2,180.00p, with a volume‑weighted average price of 2,169.64p.
The shares will be held as Treasury shares as part of GSK’s existing share buyback programme under a non‑discretionary agreement with the broker announced on 17 February 2026. Since that date, GSK has repurchased 18,546,521 ordinary shares.
After this transaction, GSK holds 258,437,615 ordinary shares in treasury and has 4,057,753,154 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.37% of the company’s voting rights.
GSK plc reported that several senior executives and persons closely associated with them acquired small amounts of GSK ordinary shares through dividend reinvestment. The transactions reflect dividends paid on 9 April 2026 being automatically used to buy additional shares in investment accounts.
On the London Stock Exchange, shares were acquired at prices around £21.50–£21.70 per share on 9 and 10 April 2026. Participants included CEO Luke Miels, who acquired 2,393.328 shares at £21.5039, and multiple presidents and senior officers, each completing a single, routine purchase.
GSK plc reported encouraging early-stage results for mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody-drug conjugate, in difficult-to-treat gynaecological cancers. In the phase 1 BEHOLD-1 trial, Mo-Rez monotherapy achieved confirmed objective response rates of 62% in platinum-resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer at the highest doses tested.
The safety profile was described as manageable: very few patients stopped treatment because of treatment-related side effects, and serious side effects were mainly blood-related, which is typical for this drug class. Interstitial lung disease or pneumonitis occurred in 3% of patients and was mild to moderate. The median duration of response had not yet been reached at this interim analysis, suggesting responses may be durable but follow-up is ongoing.
On the back of these data, GSK plans to advance Mo-Rez into five pivotal global phase III trials in 2026 across ovarian and endometrial cancer settings, including earlier-line and maintenance use. This programme underscores GSK’s broader oncology strategy focused on antibody-drug conjugates and women’s cancers.